We found a slight attenuation of NF-κB/p65 activation for 10–40 μM of apigenin tested in the three types of C57 cells (Figure 9A,B), which suggests that in skin carcinoma cells the anti-tumor effect of apigenin is not principally mediated by the inhibition of the NF-κB/p65 pathway. Here, NFKB1 is linked to skin carcinoma.